羧甲基壳聚糖抗肿瘤及免疫增强活性研究

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (12): 1390-1394.

羧甲基壳聚糖抗肿瘤及免疫增强活性研究

杨靖亚¹, 吴宏忠², 于有军², 刘建文²

¹上海水产大学食品学院,上海 200090;
²华东理工大学药学院,上海 200237

收稿日期:2007-06-29 修回日期:2007-09-30 发布日期:2020-11-10
作者简介:杨靖亚,女,博士,讲师,研究方向:肿瘤药理学。Tel:021-65711476 E-mail:jyyang@shfu.edu.cn
基金资助:
上海水产大学博士基金项目(04-166);上海市重点学科建设项目(T1102)

Studies on anti-cancer and immune enhancing effects of carboxymethyl-ch-itosan

YANG Jing-ya¹, YU You-jun², WU Hong-zhong², LIU Jian-wen²

¹College of Food Science, Shanghai Fisheries University. Shanghai 200093 China;
²College of Phamcology. Eas-China University of Science and Technology. Shanghai 200237, China

Received:2007-06-29 Revised:2007-09-30 Published:2020-11-10

摘要/Abstract

摘要： 目的: 坪价提甲基壳聚糖抗肿瘤和免疫增强活性。方法: MTT法研究提甲基壳聚糖体外活性,S180 实体瘤模型用于评价提甲基壳聚糖体内抗肿瘤活性,流式细胞术分析肿瘤细胞的周期变化和细胞凋亡,ELISA 法测定数甲基壳聚糖对免疫功能的调节。结果: 提甲基壳聚糖抑制肿瘤细胞增殖, IC₅₀为 30 µg/mL,肿瘤抑制率为 27.9% ~ 43.6%。用药后细胞周期阻滞在G₁ 期,肿瘤细胞凋亡明显增加。体内具有明显的抑瘤和免疫增强作用。结论: 发甲基壳聚糖可以通过直接杀伤肿瘤细胞和增强免疫而发挥抗肿瘤效应。

关键词: 数甲基壳聚糖, 肿瘤细胞, 增殖抑制, 免疫

Abstract: AIM: To detemine the anti-cancer andimmune-enhancing effects of carboxymethyl-chitosan. METHODS: MTT method was used to detect the activity of carboxymethyl-chitosan in vitro; S180 tumor model wasbuilt to study the antitumor ffeet of carboxymethyl-chi-tosan in tito. Flow cytonetric analysis was employed toanalysis tumor cell eyele and apoptosis. ELISA was usedto measure the immune modulation activity of carboxym-ethyi chitosan. RESULTS: Carboxymethyl-chitosan sup-pressed tumorcells. The IC₅₀ is 30 μg/mL. The cell ey-rle was arested in Gphase afer Carboxynethyi-chitsan treatment, and apoplosis of cancer cell was induced obvi-ously. Carboxymethyl-chitosan also presented proninenteffects on anti-cancer and imanune enhancement. CONCLUSION: Carboxymethyl-chitosan exhibit anti-caner effects significantly by direetly illing cancer celis and in-mune enhancement.

Key words: carboxymethyl-chitosan, tumor, multi-plication restriction, inmunity

中图分类号:

R965.2

杨靖亚, 吴宏忠, 于有军, 刘建文. 羧甲基壳聚糖抗肿瘤及免疫增强活性研究[J]. 中国临床药理学与治疗学, 2007, 12(12): 1390-1394.

YANG Jing-ya, YU You-jun, WU Hong-zhong, LIU Jian-wen. Studies on anti-cancer and immune enhancing effects of carboxymethyl-ch-itosan[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1390-1394.

参考文献

[1] 何乃苦,宋鹏飞,王荣民.甲壳素/壳聚糖及其衍生物抗菌、抗肿瘤活性研究进展[J].高分子通报,2004:14-18.
[2] Maeda Y, Kimura Y. Antitumor effects of various low-molecµlar-weight chitosaru are due to increased natural killer activity of intestinal intraepithelial nphocytes in coma 180-bearing mice[J]. J Nutr, 2004;134:945-950.
[3] Torzsas TL, Kendall CW, Sugano M, et al. influence of high and low molecµlar weight chitosan on colonic cell proliferation and aberrant crypt foci development in CF! mice[J]. Food Chem Toxicol, 1996;34:73-77.
[4] Pae HO, Seo WG,Kim NY, et al. Induction of differentiation in acutle promyelocytic leukemia cells (HL-60) bywater-soluble chitosan oligomer[J]. Leuk Res, 200l;25: 339-346.
[5] 杜昱光,白雪芳,金宗濂,等.壳寡糖抑制肿瘤作用的研究[J].中国海洋药物,2002;21:18-21.
[6] 赵呈裕,杨英,李虹,等.毛柄金钱菌水溶性多糖抑制小鼠S180实体瘤生长的研究[J].华西医科大学学报,1988;19-20.
[7] 蒋挺大, 壳聚糖[M] 壳聚糖[M].北京:化学工业出版社,2001:1-5.
[8] Muzzarelli RAA. Human enzymatic activities related to the ther-apeutical administration of chitin derivatives[J]. Cell Mol LifeSci, 1997;53:131-140.
[9] Dumitriu S. Polysaccharides, structural diversity and funetionalversatility[M]. New York: Marcel Dekker, 1998;31:223-246.10 Majeti NV, Ravi Kumar. A review of chitin and chitosan appli-cations[J]J. React Functional Polym, 2000;46:1-27.
[10] 张文清,柴平海,夏玮.NaOC/H2O2协同氧化制备壳寡糖[J].华东理工大学学报,200:26:425-428.
[11] 杨靖亚,刘建文,刘承初,等.羧甲基壳聚糖对人高转移肺癌细胞-95D增殖能力和体外转移能力的抑制作用[].中国临床药理学与治疗学,206:1:6-9.
[12] Ueno H, Morl T, Fujinaga T. Chiosan nan oariles: a newvehicle for the improvement of the delivery of drugs to the ocularsurface[J]. Adv Drug Deliv Rev, 2001;52: 105-115.
[13] Cho YW, Cho YN, Chung SH, et al. Water-soluble chitin as a wound healing accelerator[J]. Biomaterials, 1999;20: 2139-2145.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	乔红亮, 丁宁, 邓凯红, 刘彬彬, 董传江, 陈晓波, 邹黎黎. 耐甲氧西林金黄色葡萄球菌感染新型控制策略研究新进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 676-687.
[4]	李阳, 潘维忠, 张晓录, 于翠翠. 回收式自体血回输对行剖宫产术患者免疫功能及炎症反应的影响[J]. 中国临床药理学与治疗学, 2023, 28(5): 514-524.
[5]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[6]	刘佳君, 阙祖俊, 田建辉. 金复康有效成分抑制肺癌循环肿瘤细胞募集中性粒细胞能力的比较研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 1-9.
[7]	杜文鹏, 敖检根, 陶祎, 吴观胜, 何佳珂. 自身免疫疾病患者他克莫司稳态血药浓度影响因素的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 645-651.
[8]	孟时, 王中群. 人类免疫缺陷病毒相关性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1431-1440.
[9]	邓颖, 白殊同. 金圣草黄素相关药理作用机制的研究进展 [J]. 中国临床药理学与治疗学, 2022, 27(10): 1155-1162.
[10]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[11]	李玮, 胡佳丽, 王凯, 贺毅憬. 黑色素瘤免疫治疗的研究现状与展望[J]. 中国临床药理学与治疗学, 2021, 26(9): 1053-1064.
[12]	彭静, 宋静, 栾家杰. 新型冠状病毒肺炎治疗新策略：间充质干细胞疗法[J]. 中国临床药理学与治疗学, 2021, 26(9): 1073-1079.
[13]	车津晶, 李娜. 生物类似药临床免疫原性相似性评价生物分析方法的一般考虑[J]. 中国临床药理学与治疗学, 2021, 26(7): 721-728.
[14]	章权, 石仕元, 韩贵和. 1,25二羟维生素D3在脊柱结核治疗中的免疫调节作用[J]. 中国临床药理学与治疗学, 2021, 26(7): 787-793.
[15]	路明, 尹晓玉, 张志清. 间充质干细胞对自身免疫病治疗作用研究进展及机制探究[J]. 中国临床药理学与治疗学, 2021, 26(6): 700-706.